Description
FOLH1 Antibody | 18-999 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: A synthetic peptide of human FOLH1
Research Area: Cancer, Signal Transduction
Tested Application: WB, IHC, IF
Application: WB: 1:500 - 1:1000
IHC: 1:20 - 1:50
IF: 1:20 - 1:50
Specificiy: N/A
Positive Control 1: DU145
Positive Control 2: SKOV3
Positive Control 3: 293T
Positive Control 4: SGC-7901
Positive Control 5: HT-29
Positive Control 6: MCF7
Molecular Weight: Observed: 120kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, pH7.3.
Concentration: N/A
Storage Condition: Store at 4˚C. Avoid freeze / thaw cycles.
Alternate Name: FOLH1, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney. A mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia. Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity. In the prostate the protein is up-regulated in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer. This gene likely arose from a duplication event of a nearby chromosomal region. Alternative splicing gives rise to multiple transcript variants encoding several different isoforms.